BACKGROUND: Low striatal dopamine 2/3 receptor (D(2/3)) availability and low ventrostriatal dopamine (DA) release have been observed in alcoholism and cocaine and heroin dependence. Less is known about the dopaminergic system in cannabis dependence. We assessed D(2/3) availability and DA release in abstinent cannabis users compared with control subjects and explored relationships to cannabis use history using [(11)C]raclopride positron emission tomography and an amphetamine challenge paradigm. METHODS: Sixteen recently abstinent, psychiatrically healthy cannabis-using participants (27.3 ± 6.1 years, 1 woman, 15 men) and 16 matched control subjects (28.1 ± 6.7 years, 2 women, 14 men) completed two positron emission tomography scans, before and after injection of intravenous d-amphetamine (.3 mg/kg). Percent change in [(11)C]raclopride binding after amphetamine (change in nondisplaceable binding potential, ΔBP(ND)) in subregions of the striatum was compared between groups. Correlations with clinical parameters were examined. RESULTS: Cannabis users had an average consumption of 517 ± 465 estimated puffs per month, indicating mild to moderate cannabis dependence. Neither baseline BP(ND) nor ΔBP(ND) differed from control subjects in any region of interest, including ventral striatum. In cannabis-dependent subjects, earlier age of onset of use correlated with lower [ΔBP(ND)] in the associative striatum when controlling for current age. CONCLUSIONS: Unlike other addictions, cannabis dependence of mild to moderate severity is not associated with striatal DA alterations. However, earlier or longer duration of use is related to lower DA release in the associative striatum. These observations suggest a more harmful effect of use during adolescence; more research is needed to distinguish effects of chronicity versus onset.
BACKGROUND: Low striatal dopamine 2/3 receptor (D(2/3)) availability and low ventrostriatal dopamine (DA) release have been observed in alcoholism and cocaine and heroin dependence. Less is known about the dopaminergic system in cannabis dependence. We assessed D(2/3) availability and DA release in abstinent cannabis users compared with control subjects and explored relationships to cannabis use history using [(11)C]raclopride positron emission tomography and an amphetamine challenge paradigm. METHODS: Sixteen recently abstinent, psychiatrically healthy cannabis-using participants (27.3 ± 6.1 years, 1 woman, 15 men) and 16 matched control subjects (28.1 ± 6.7 years, 2 women, 14 men) completed two positron emission tomography scans, before and after injection of intravenous d-amphetamine (.3 mg/kg). Percent change in [(11)C]raclopride binding after amphetamine (change in nondisplaceable binding potential, ΔBP(ND)) in subregions of the striatum was compared between groups. Correlations with clinical parameters were examined. RESULTS: Cannabis users had an average consumption of 517 ± 465 estimated puffs per month, indicating mild to moderate cannabis dependence. Neither baseline BP(ND) nor ΔBP(ND) differed from control subjects in any region of interest, including ventral striatum. In cannabis-dependent subjects, earlier age of onset of use correlated with lower [ΔBP(ND)] in the associative striatum when controlling for current age. CONCLUSIONS: Unlike other addictions, cannabis dependence of mild to moderate severity is not associated with striatal DA alterations. However, earlier or longer duration of use is related to lower DA release in the associative striatum. These observations suggest a more harmful effect of use during adolescence; more research is needed to distinguish effects of chronicity versus onset.
Authors: Mark van der Gaag; Tonko Hoffman; Mila Remijsen; Ron Hijman; Lieuwe de Haan; Berno van Meijel; Peter N van Harten; Lucia Valmaggia; Marc de Hert; Anke Cuijpers; Durk Wiersma Journal: Schizophr Res Date: 2006-05-26 Impact factor: 4.939
Authors: Diana Martinez; Rajesh Narendran; Richard W Foltin; Mark Slifstein; Dah-Ren Hwang; Allegra Broft; Yiyun Huang; Thomas B Cooper; Marian W Fischman; Herbert D Kleber; Marc Laruelle Journal: Am J Psychiatry Date: 2007-04 Impact factor: 18.112
Authors: Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis Journal: Lancet Date: 2007-07-28 Impact factor: 79.321
Authors: Nora D Volkow; Gene-Jack Wang; Frank Telang; Joanna S Fowler; David Alexoff; Jean Logan; Millard Jayne; Christopher Wong; Dardo Tomasi Journal: Proc Natl Acad Sci U S A Date: 2014-07-14 Impact factor: 11.205
Authors: Jason P Connor; Daniel Stjepanović; Bernard Le Foll; Eva Hoch; Alan J Budney; Wayne D Hall Journal: Nat Rev Dis Primers Date: 2021-02-25 Impact factor: 52.329
Authors: Felicia Kamp; Lisa Proebstl; Nora Penzel; Kristina Adorjan; Andrej Ilankovic; Oliver Pogarell; Gabi Koller; Michael Soyka; Peter Falkai; Nikolaos Koutsouleris; Joseph Kambeitz Journal: Neuropsychopharmacology Date: 2018-08-27 Impact factor: 7.853
Authors: Maria Scherma; Christian Dessì; Anna Lisa Muntoni; Salvatore Lecca; Valentina Satta; Antonio Luchicchi; Marco Pistis; Leigh V Panlilio; Liana Fattore; Steven R Goldberg; Walter Fratta; Paola Fadda Journal: Neuropsychopharmacology Date: 2015-09-21 Impact factor: 7.853
Authors: Daniel S Albrecht; Patrick D Skosnik; Jennifer M Vollmer; Margaret S Brumbaugh; Kevin M Perry; Bruce H Mock; Qi-Huang Zheng; Lauren A Federici; Elizabeth A Patton; Christine M Herring; Karmen K Yoder Journal: Drug Alcohol Depend Date: 2012-08-19 Impact factor: 4.492